Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$46.13 USD
+1.33 (2.97%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $46.14 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SUPN 46.13 +1.33(2.97%)
Will SUPN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen Gets EU Nod for First Postpartum Depression Drug
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Other News for SUPN
Is SUPN likely to continue lower? 20 Day Moving Average Resistance shows up after rising 1.84%
SUPN forms NR7 on September 16
Supernus Pharmaceuticals: Heading In The Right Direction
SUPN Fell Below 20 Day Moving Average on September 15
Top Executive Sells Thousands of Supernus Pharmaceuticals Shares!